Nucana announces grant of composition-of-matter patent for nuc-7738 in the united states

Edinburgh, united kingdom, sept. 25, 2024 (globe newswire) -- nucana plc (nasdaq: ncna) announced the issuance of a new patent by the united states patent and trademark office (uspto) covering nuc-7738's composition of matter. this patent (us12,054,510) is expected to serve as a key component of the intellectual property protection for nuc-7738, which currently consists of over 80 issued patents worldwide. nuc-7738 is a novel anti-cancer agent currently in a phase 2 clinical study in combination with pembrolizumab in pd-1 inhibitor resistant melanoma patients, for which nucana presented encouraging data at the esmo congress 2024 earlier this month.
NCNA Ratings Summary
NCNA Quant Ranking